4D Molecular Therapeutics appoints Kristian Humer as CFO effective Nov 17, 2025

4D Molecular Therapeutics, Inc.

Kristian Humer, formerly CFO at Foghorn Therapeutics and Viridian Therapeutics, joins as CFO and Principal Financial Officer.
Compensation includes $520K base salary, 40% target bonus, option for 480K shares, and $100K sign-on bonus paid in two installments.
Severance: 9 months base salary + COBRA if terminated w/o cause or for good reason; 12 months + COBRA plus full equity acceleration if within 12 months of a change in control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.